Microbiota management: a perspective for kidney transplant patients.

Frontiers in transplantation Pub Date : 2026-02-19 eCollection Date: 2026-01-01 DOI:10.3389/frtra.2026.1703048
Cláudia Silva Souza, Niels Olsen Saraiva Camara, Thaís Alves-Silva
{"title":"Microbiota management: a perspective for kidney transplant patients.","authors":"Cláudia Silva Souza, Niels Olsen Saraiva Camara, Thaís Alves-Silva","doi":"10.3389/frtra.2026.1703048","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic kidney disease (CKD) is recognized as one of the most significant public health issues globally, with approximately 40% of patients progressing to end-stage kidney disease (ESKD). Transplantation remains the most indicated option for many patients with ESKD; however, these individuals frequently experience hospital readmissions and face a heightened risk of developing other complications. Although short-term allograft survival, typically around one year, tends to be satisfactory, long-term graft survival is often compromised due to acute and chronic rejection, which can be mediated by antibodies or other recipient-related factors. Recent studies and review articles have emphasized the relationship between intestinal dysbiosis and chronic renal failure, as well as the poor outcomes associated with kidney transplantation. The CKD itself, as well as the immunosuppressive medications used by organ transplant recipients, can lead to intestinal dysbiosis, which in turn increases the production of uremic toxins that can harm even the transplanted kidney. Clinical studies have demonstrated that the combination of prebiotics, probiotics, and synbiotics-supplements that aid in the establishment of intestinal microbiota-can effectively help control the production of nitrogenous substances, reduce renal inflammation, and alleviate gastrointestinal symptoms in patients with CKD. Experimental models have shown that short-chain fatty acids derived from gut fermentation of dietary fiber, such as butyrate and acetate, could improve renal function and reduce renal inflammation, allowing better acceptance of kidney allograft, partly by inducing T regulatory cells. Despite the growing evidence supporting the positive effects of maintaining a balanced microbiota, there is still a lack of comprehensive reviews in this field. Additionally, recent findings suggest that the type of fiber consumed may influence intestinal health and even increase susceptibility to colorectal cancer, depending on the fiber type. Therefore, we aim to explore how substances derived from gut fermentation of dietary fiber, in addition to probiotics, prebiotics, and synbiotics, contribute to allograft tolerance, with a particular focus on their potential application in establishing renal function in allograft recipients.</p>","PeriodicalId":519976,"journal":{"name":"Frontiers in transplantation","volume":"5 ","pages":"1703048"},"PeriodicalIF":0.0000,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960561/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/frtra.2026.1703048","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic kidney disease (CKD) is recognized as one of the most significant public health issues globally, with approximately 40% of patients progressing to end-stage kidney disease (ESKD). Transplantation remains the most indicated option for many patients with ESKD; however, these individuals frequently experience hospital readmissions and face a heightened risk of developing other complications. Although short-term allograft survival, typically around one year, tends to be satisfactory, long-term graft survival is often compromised due to acute and chronic rejection, which can be mediated by antibodies or other recipient-related factors. Recent studies and review articles have emphasized the relationship between intestinal dysbiosis and chronic renal failure, as well as the poor outcomes associated with kidney transplantation. The CKD itself, as well as the immunosuppressive medications used by organ transplant recipients, can lead to intestinal dysbiosis, which in turn increases the production of uremic toxins that can harm even the transplanted kidney. Clinical studies have demonstrated that the combination of prebiotics, probiotics, and synbiotics-supplements that aid in the establishment of intestinal microbiota-can effectively help control the production of nitrogenous substances, reduce renal inflammation, and alleviate gastrointestinal symptoms in patients with CKD. Experimental models have shown that short-chain fatty acids derived from gut fermentation of dietary fiber, such as butyrate and acetate, could improve renal function and reduce renal inflammation, allowing better acceptance of kidney allograft, partly by inducing T regulatory cells. Despite the growing evidence supporting the positive effects of maintaining a balanced microbiota, there is still a lack of comprehensive reviews in this field. Additionally, recent findings suggest that the type of fiber consumed may influence intestinal health and even increase susceptibility to colorectal cancer, depending on the fiber type. Therefore, we aim to explore how substances derived from gut fermentation of dietary fiber, in addition to probiotics, prebiotics, and synbiotics, contribute to allograft tolerance, with a particular focus on their potential application in establishing renal function in allograft recipients.

Abstract Image

微生物群管理:肾移植患者的视角。
慢性肾脏疾病(CKD)被认为是全球最重要的公共卫生问题之一,大约40%的患者进展为终末期肾脏疾病(ESKD)。移植仍然是许多ESKD患者最适合的选择;然而,这些人经常经历医院再入院,并面临发展其他并发症的高风险。虽然同种异体移植物的短期存活,通常在一年左右,往往是令人满意的,但长期存活往往受到急性和慢性排斥反应的影响,这可能是由抗体或其他受体相关因素介导的。最近的研究和综述文章强调了肠道生态失调与慢性肾功能衰竭的关系,以及与肾移植相关的不良预后。CKD本身,以及器官移植接受者使用的免疫抑制药物,会导致肠道生态失调,进而增加尿毒症毒素的产生,甚至会损害移植的肾脏。临床研究表明,益生元、益生菌和辅助肠道微生物群建立的合成制剂联合使用,可以有效控制CKD患者体内含氮物质的产生,减轻肾脏炎症,缓解胃肠道症状。实验模型表明,从膳食纤维肠道发酵中提取的短链脂肪酸,如丁酸盐和醋酸盐,可以改善肾功能,减少肾脏炎症,使肾脏更好地接受同种异体移植,部分原因是通过诱导T调节细胞。尽管越来越多的证据支持维持平衡的微生物群的积极作用,但在这一领域仍然缺乏全面的综述。此外,最近的研究结果表明,摄入的纤维类型可能会影响肠道健康,甚至会增加对结肠直肠癌的易感性,这取决于纤维的类型。因此,我们的目标是探索膳食纤维肠道发酵产生的物质,以及益生菌、益生元和合成菌,如何促进同种异体移植耐受,并特别关注它们在建立同种异体移植受体肾功能方面的潜在应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书